source
- IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costsIQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
- Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancersEli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…